tbuckley/cabot-search huggingface dataset:
Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.
Authors: Joleen Marie Hubbard, George P. Kim, Mitesh J. Borad, Rui Qin, Janet Lensing, John Joseph Wright, Charles Erlichman, Axel Grothey
Journal: Journal of Clinical Oncology (2014)

2539 Background: Sorafenib inhibits various pro-angiogenesis pathways including PDGFR-B, a factor associated with resistance to anti-VEGF therapy. A previous phase II trial in patients with chemorefractory metastatic CRC demonstrated a 63% disease control rate with a combination of bevacizumab (BEV) and sorafenib. This phase I trial sought to determine the MTD of BEV and sorafenib combined with standard cytotoxic therapy for advanced gastrointestinal (GI) cancers. Methods: Patients with advanced GI malignancies appropriate for irinotecan-based therapy were enrolled (14 with CRC, 3 gastroesophageal). A standard 3 + 3 design was used with 3 escalating sorafenib dose levels (DL): (1) 200 mg po daily, days 3-7, 10-14; (2) 200 mg po twice daily, days 3-6, 10-13; and (3) 200 mg po twice daily, days 3-7, 10-14. FOLFIRI: irinotecan 180 mg/m2 d1, leucovorin 400 mg/m2 d1, 5-fluorouracil (FU) bolus 400 mg/m2 d1, 5-FU infusion 2400 mg/m2d1-2 and BEV 5 mg/kg d1. 1 cycle = 14 days. Results: Seventeen pts were enrolled, median age of 56 (range 32 and 81). Two pts were replaced, as they did not complete DLT evaluation, leaving 15 evaluable pts. Four evaluable pts at DL1 and 6 pts at DL2 had no DLTs. At DL 3, the first cohort of 3 pts did not experience any DLTs. In the second cohort of 3 pts, 2 pts experienced DLTs (asymptomatic G3 hypophosphatemia, G3 dehydration and diarrhea). MTD was determined to be DL2: sorafenib 200 mg PO twice daily, days 3-6, 10-13 combined with FOLFIRI and BEV at standard doses. Of the 15 evaluable pts, 4 pts had PR, 8 pts had SD as best response, 1 pt had PD, and 2 pts discontinued treatment prior to first tumor assessment. The median number of cycles was 12 (range 1 - 46). Three pts with CRC had disease control > 12 months. Conclusions: The MTD of this regimen is sorafenib 200 mg PO twice daily, Days 3-6,10-13 combined with standard doses of FOLFIRI and BEV. Dual VEGF inhibition combined with cytotoxic therapy may provide prolonged disease stabilization for select patients with advanced GI malignancies. Clinical trial information: NCT01383343.
Lymphoma of the Small Intestine with Malabsorption Syndrome and Pneumatosis Intestinalis
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Blood banking not what it used to be, experts say
Authors: A. A. Skolnick
Journal: JAMA (1994)

IN THE WORDS of one speaker at the American Association of Blood Banks conference, Transfusion Medicine: Update 1994, held in Seattle, Wash, "Blood banking has changed. We are no longer the blood bankers we used to be." Merlin Sayers, MD, PhD, director, Transfusion Surveillance, Puget Sound Blood Center, Seattle, who provided an update on hepatitis virology, cited his own topic as an example of how different the conference program is compared with the topics that concerned blood bankers 10 or more years ago. Indeed, a major part of the 2-day conference included sessions on tissue banking, extracorporeal membrane oxygenation, transfusion-associated graft-vs-host disease, blood conservation during surgery, and red blood cell substitutes, as well as more traditional areas of interest to blood bankers. Based on reports presented at the update of promising new technologies for reducing or eliminating the need for blood transfusions, even greater changes appear to lie ahead. <h3>Blood</h3>
Humanitarianism Survives, Despite Being Under the Gun
Authors: Ranit Mishori
Journal: JAMA (1997)

<h3>To the Editor.</h3> —I read the article by Drs Sharp and Shenson<sup>1</sup>with great interest. As a journalist I have visited many trouble spots and war zones, often traveling with relief workers and volunteer physicians. Journalists, as well as humanitarian workers, have frequently been harassed, jailed, and even killed trying to tell stories of refugees, displaced persons, and other victims—dead or alive—of armed conflicts around the world.<sup>2</sup>Those incidents, too, have many times been met with a deafening silence on the part of Western governments. Throughout my journalistic career, I have been deeply impressed by the work of relief agencies, such as Doctors of the World, and touched by the dedication and enthusiasm of the medical personnel despite the great risk to their lives. It was during one of my assignments—to Bosnia in the winter of 1994—that I was inspired by some volunteer physicians in a dingy and
UREA AS A FIBRIN SOLVENT
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Letters to the Editor
Authors: Philip Cole, M.D., Robert Hoover, M.D.
Journal: JNCI Journal of the National Cancer Institute (1971)

Letters to the Editor Get access Philip Cole, M.D., Philip Cole, M.D. Assistant Professor Teaching Fellow Harvard University School of Public Health Boston, Massachusetts 02115 Search for other works by this author on: Oxford Academic PubMed Google Scholar Robert Hoover, M.D. Robert Hoover, M.D. Teaching Fellow Harvard University School of Public Health Boston, Massachusetts 02115 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 46, Issue 5, May 1971, Pages 1111–1112, https://doi.org/10.1093/jnci/46.5.1111 Published: 01 May 1971
Les Cardio-Rénaux. Étude Théorique et Pratique.
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mechanisms of Altered Excitation-Contraction Coupling in Canine Tachycardia-Induced Heart Failure, I
Authors: Brian O’Rourke, David A. Kass, Gordon F. Tomaselli, Stefan Kääb, Richard Tunin, Eduardo Marbán
Journal: Circulation Research (1999)

Abstract —Pacing-induced heart failure in the dog recapitulates many of the electrophysiological and hemodynamic abnormalities of the human disease; however, the mechanisms underlying altered Ca 2+ handling have not been investigated in this model. We now show that left ventricular midmyocardial myocytes isolated from dogs subjected to 3 to 4 weeks of rapid pacing have prolonged action potentials and Ca 2+ transients with reduced peaks, but durations ≈3-fold longer than controls. To discriminate between action potential effects on Ca 2+ kinetics and direct changes in Ca 2+ regulatory processes, voltage-clamp steps were used to examine the time constant for cytosolic Ca 2+ removal (τ Ca ). τ Ca was prolonged by just 35% in myocytes from failing hearts after fixed voltage steps in physiological solutions (τ Ca control, 216±25 ms, n=17; τ Ca failing, 292±23 ms, n=22; P &lt;0.05), but this difference was markedly accentuated when Na + /Ca 2+ exchange was eliminated (τ Ca control, 282±30 ms, n=13; τ Ca failing, 576±83 ms, n=11; P &lt;0.005). Impaired sarcoplasmic reticular (SR) Ca 2+ uptake and a greater dependence on Na + /Ca 2+ exchange for cytosolic Ca 2+ removal was confirmed by inhibiting SR Ca 2+ ATPase with cyclopiazonic acid, which slowed Ca 2+ removal more in control than in failing myocytes. β-Adrenergic stimulation of SR Ca 2+ uptake in cells from failing hearts sufficed only to accelerate τ Ca to the range of unstimulated controls. Protein levels of SERCA2a, phospholamban, and Na + /Ca 2+ exchanger revealed a pattern of changes qualitatively similar to the functional measurements; SERCA2a and phospholamban were both reduced in failing hearts by 28%, and Na + /Ca 2+ exchange protein was increased 104% relative to controls. Thus, SR Ca 2+ uptake is markedly downregulated in failing hearts, but this defect is partially compensated by enhanced Na + /Ca 2+ exchange. The alterations are similar to those reported in human heart failure, which reinforces the utility of the pacing-induced dog model as a surrogate for the human disease.
Breathing Easier
Authors: Rebecca Voelker
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Institute of Medicine calls for coordinated studies of Gulf War veterans' health complaints
Authors: P. Gunby
Journal: JAMA (1995)

FEDERAL AGENCIES must redirect and coordinate data collection and research efforts, an Institute of Medicine (IOM) committee says, if answers are to be found to health questions raised by Persian Gulf War veterans (<i>JAMA</i>. 1994; 272:341). Following continued reports from some veterans that they (and sometimes their families) are inexplicably ill, apparently as a result of military service during the 1991 Desert Storm liberation of Kuwait, Congress turned late in 1993 to the Washington, DC—based IOM, a 25-year-old private, nonprofit organization providing health policy advice under the 1863 congressional charter to the National Academy of Sciences. An 18-member IOM committee now has recommended, among other things, some epidemiologic studies using a population-based survey (of those who served in southwest Asia) to learn whether, and how much, the frequency of these mystery illnesses in Persian Gulf veterans exceeds that in the civilian population. The committee also recommends a single service-connected health
YELLOW FEVER INVESTIGATION BY THE MARINEHOSPITAL SERVICE.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Stratification in Intravenous Cholangiography. A Case Report
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 4999: Characterization of myeloid derived suppressor cells after capecitabine and nivolumab combination treatment
Authors: Qing Lin, Tienan Wang, Wenjun Yan, Ranran Wu, Lun Nie, Chensi Miao, Xing Wang, Feng Wang, Jie Zhang, Weilin Shi, Yanping Yuan, Tingting Shi, Ao Li, Wei Dong, Xu Chen, Jingying Sun, Qunsheng Ji
Journal: Cancer Research (2019)

Abstract Capecitabine, a widely used oral chemotherapeutic agent, only functions in its active form, 5-FU. The metabolism of capecitabine to 5-FU frequently occurs in tumor tissues with high expression of thymidine phosphorylase, enzyme responsible for converting capecitabine. Extensive studies have demonstrated that capecitabine functions to inhibit growth of tumors, especially for metastatic breast and colorectal tumors, by impairing DNA synthesis and metabolism. However, effects of capecitabine on myeloid derived suppressor cell (MDSC) in the tumor microenvironment are poorly understood. In fact, conflicting results were reported that capecitabine either reduced CD11bhigh/Gr1high MDSC and enhanced T cell functions, or failed to alter the number and function of MDSC or the levels of GM-CSF/IL6 in blood. In this study, we established an optimized in-vitro MDSC suppressive assay and take the advantage of this system to investigate the function of capecitabine on MDSC-mediated T cell suppression. Myeloid cells in tumor environment acquire the expression of PD-L1, suggesting that blocking the PD1-PD-L1 axis might revert the function of MDSC. Therefore, we further explored the combination effect of capecitabine and nivolumab, a PD-1 antibody, on the function of MDSC in human PBMC cells. Citation Format: Qing Lin, Tienan Wang, Wenjun Yan, Ranran Wu, Lun Nie, Chensi Miao, Xing Wang, Feng Wang, Jie Zhang, Weilin Shi, Yanping Yuan, Tingting Shi, Ao Li, Wei Dong, Xu Chen, Jingying Sun, Qunsheng Ji. Characterization of myeloid derived suppressor cells after capecitabine and nivolumab combination treatment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4999.
Dose-finding study of interferon alfa-n3 in hepatitis
Authors: J Hoofnagle
Journal: Hepatology (1997)

Normal Heterozygotes Homozygotes TotalA significant association between genetic hemochromato-A1ATD, liver disease 33 (82.5%) 7 (17.5%)0 (0%) 40 sis (GH) and a 1 -antitrypsin deficiency (A1ATD) has been A1ATD, no liver reported by Rabinovitz et al. 1 in patients with severe liver disease 32 (82.1%) 7 (17.9%)0 (0%) 39 disease.It has been suggested that there is an additive effect Controls 159 (86.9%) 22 (12.0%) 2 (1.1%) 183 of hepatic iron storage and hepatocyte damage from the ab-Published data 5 326 (88.6%) 40 (10.9%) 2 (0.5%) 368normally folded PiZ or PiS protein.There could also be some interaction of the mutant A1ATD gene and the hemochromatosis gene by a previously undescribed mechanism, involving a third gene, resulting in liver disease even before hematolog-There is no difference between the hemochromatosis muical evidence of iron accumulation. 1However, Fargion et al. 2 tation frequency in those A1ATD patients with liver disease reported no relationship between these conditions identi-(17.5%) and without liver disease (17.9%).It is of interest fying GH by hematological indices and liver biopsy in pathat the frequency of heterozygotes in patients with A1ATD tients with and without cirrhosis.(17.7%) is higher than in individuals without A1ATD.How-Ninety percent of patients from Britain with GH are homoever, this difference does not reach statistical significance (% zygous for the C282Y (845G r A) mutation in the hemochrodifference: 5.5%; 95% confidence interval: 7.2%-18.2%).Our matosis (HLA-H) gene.Homozygosity for GH is estimated control heterozygote frequency is higher than that published at up to 5 per 1,000 in Europe, 3 with a carrier frequency of for the U.K. British population and represents local popula-10% to 17%.tion variation.To investigate the possibility of an interaction between the These results show that possession of the hemochromatotwo conditions resulting in chronic liver disease, we used sis mutation is not a risk factor for liver disease in A1ATD.molecular biological techniques to study 79 A1ATD patients in the United Kingdom with the PiZZ or PiSZ mutations Acknowledgment: Supported by grant 179, The Children's confirmed by isoelectric focusing.Forty patients were reappeal, Sheffield, UK (to M.J.S.).The authors thank Dr. S. ferred in childhood because of liver disease, and were found Povey for donation of DNA from A1ATD patients and Dr. D. to have fibrosis or cirrhosis on liver biopsy.Thirty-nine indi-Curtis for her assistance with development of the molecular viduals had no evidence of liver disease into adult life, 21 biology techniques.were clinically normal, and 18 had emphysema.We used the polymerase chain reaction (PCR) and restric-MARK J. SHARRARD, M.R.C.P. tion fragment length polymorphism to investigate these pa-MIRANDA DURKIE, B.SC. tients for the C282Y mutation.A modified PCR was devel-M.
LETTERS, NOTES, AND ANSWERS TO CORRESPONDENTS
Journal: BMJ (1902)

JOURNAL is Articulate.London.Querie8, answer, and communieatiotes relatg to subjects to uhich sp6ecial departments of the BRiTISH MEDICAL JOURNAL are devoted wiU be found under their respective headings.A. P. S. wishes to hear of a winter resort iD the British Isles suitable for asthma, and asks whether Glengariff would be beneficial.T. Q. asks whether any savage nation uses or ever did use any part of the human cadaver for the purpose of poisoning their arrows, or where he might find information on the subject ?INCOME TAX.R. R. writes: I have a resident patient who pays me 4 guineas a week; this covers board and residence, wine, medicine, and all necessary expenses, including afortnight atthe seaside
THYROID GLANDS.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal